Abstracts tagged "Fibromyalgia and population studies"

Abstract Number: 1106 • 2014 ACR/ARHP Annual Meeting
Most Patients Diagnosed with Fibromyalgia By Physicians Do Not Have Fibromyalgia: The 2012 National Health Interview Survey Fibromyalgia Study
Brian Walitt¹, Richard Nahin², Robert S. Katz³, Martin J. Bergman⁴ and Frederick Wolfe⁵, ¹MedStar Health, Washington, DC, ²National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethedsa, MD, ³Rush Medical College, Chicago, IL, ⁴Taylor Hospital, Ridley Park, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Although criteria exist for fibromyalgia (FM) diagnosis, little is known about how FM diagnosis is applied and understood by physicians and patients in the…
Abstract Number: 896 • 2014 ACR/ARHP Annual Meeting
Development of Fibromyalgia and Polysymptomatic Distress Definitions in the National Health Interview Survey
Brian Walitt¹, Richard Nahin², Robert S. Katz³, Martin J. Bergman⁴ and Frederick Wolfe⁵, ¹MedStar Health, Washington, DC, ²National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethedsa, MD, ³Rush Medical College, Chicago, IL, ⁴Taylor Hospital, Ridley Park, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: A detailed understanding of fibromyalgia and its symptoms in the US population would be valuable. The National Health Interview Survey (NHIS) is the principal…
Abstract Number: 137 • 2013 ACR/ARHP Annual Meeting
A Population-Based Survey and Physician Assessment Of The Characteristics and Prevalence Of Fibromyalgia
Edgar H. Adams¹, Shoshana Daniel², Arthi B. Chandran³, Heather McElroy⁴, Caroline Schaefer¹, Rachael Mann⁵, Gergana Zlateva³, Joseph C. Cappelleri⁶, Elizabeth T. Masters⁷, Annlouise R. Assaf⁶, Michael McNett⁸, Stuart L. Silverman⁹, Roland Staud¹⁰ and Philip Mease¹¹, ¹Covance Market Access Services Inc., Gaithersburg, MD, ²Covance Market Access Services Inc., Conshohocken, PA, ³Pfizer Inc., New York, NY, ⁴Covance Market Access Services, Sydney, Australia, ⁵Covance Market Access Services Inc., San Diego, CA, ⁶Pfizer Inc., Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Aurora Pain Program, Milwaukee, WI, ⁹Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA, ¹⁰Dept Med/Rheum/Clin Immun Div, University of Florida, Gainesville, FL, ¹¹Director, Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: No large-scale, national study estimating fibromyalgia (FM) prevalence in the United States (US) has been conducted involving physician evaluation. The study objective was to…
Abstract Number: 1859 • 2012 ACR/ARHP Annual Meeting
The Polysymptomatic Distress Scale and the Effect of Age On Polysymptomatic Distress and Fibromyalgia: A Survey in a Representative Population Sample
Winfried Häuser¹, Frederick Wolfe², Johannes Rasker³, Elmar Brähler⁴ and Heide Glaesmer⁴, ¹Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Dpt. Psychology, Health and Technology, University Twente, Enschede, Netherlands, ⁴University of Leipzig, Leipzig, Germany
Background/Purpose : Recent advances in the definition of the fibromyalgia syndrome (FM) have led to the development of the polysymptomatic distress (PSD) scale, providing a…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.